Foundation system

The Paula & Rodger Riney Foundation provides $5.9 million to accelerate multiple myeloma research

Donation supports research over next two years at MCW Cancer Center

MILWAUKEE, August 25, 2022 /PRNewswire/ — The Paula & Rodger Riney Foundation provides $5.9 million to Wisconsin Medical College (MCW) to advance new scientific and clinical discoveries in multiple myeloma research focused on immunotherapies and long-term patient survival.

“We are thrilled to partner with the MCW Cancer Center in our shared aspiration to find a cure for multiple myeloma,” said Rodger Riney. “Since the Foundation’s inception, we have sought out the most innovative work in the field, and we are very excited about the promise that MCW’s research is showing for the treatment of this complex disease.”

For more than two decades, MCW has worked closely with healthcare partners to provide patients with research-based myeloma clinical care and access to some of the most important cancer clinical trials and medical discoveries. from the country. This includes key discoveries in immune therapies – an approach that deploys the body’s natural immune defenses to slow the spread of cancer cells.

This investment from the Paula and Rodger Riney Foundation marks another significant gain in momentum for the MCW Cancer Center in the fight against cancer and ranks its efforts among other notable Foundation grantees, including the Dana-Farber Cancer Institute, the Mass General Cancer Center and the Mayo Clinic.

Along with MCW’s experience in leading and participating in first-in-man clinical trials, the institution is a major source of new discoveries in multiple myeloma and related cancers.

MCW was among the first institutions in the world to produce its own source of CAR T cells designed to target two antigens to cancerous tumors and elicit an immune response from the body. This work began in 2017 in a phase I clinical trial and led to safe and promising results for patients with cancers of the immune system. It is now part of a multi-institutional phase II trial to determine outcomes in a larger number of patients.

This investment from the Paula & Rodger Riney Foundation will support cancer research projects over the next two years and support the continued advancement of MCW’s work in the area of ​​immunotherapies to treat long-term myeloma patient survivors.

“We are grateful for this transformative support from the Paula and Rodger Riney Foundation,” said Gustave Leon, PhD, Director of the MCW Cancer Center and Dr. Glenn R. and Nancy A. Linnerson Endowed Chair for Cancer Research. “There has never been a more exciting time to be at the forefront of this pioneering research. The scientific advances we will achieve with this gift will bring much-needed benefits to generations of patients and families faced with a diagnosis of multiple myeloma.

THE SOURCE Wisconsin Medical College